By Kelly Cloonan
American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer.
Immutep climbed 16% to $2.11 on Thursday. The ADRs have declined 25% over the past 12 months.
The late-stage immunotherapy company said Thursday the combination of its Efti with Merck's Keytruda showed a 60.8% response rate for patients with advanced or metastatic non-squamous non-small cell lung cancer, compared to a historical control of 48%.
The combination also demonstrated a 90.2% disease control rate, the company said.
The combination involves eftilagimod alpha in combination with anti-PD-1 therapy Keytruda and doublet chemotherapy as first-line treatment.
Chief Executive Marc Voigt said the company's confidence in its efti treatment continues to rise with the latest trial data. Immutep now has data from 165 patients treated with the combination, with or without chemotherapy.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 15, 2025 11:36 ET (15:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.